Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia

Darren Lee, Yazan Abu-Shihab, Kate Plas, Deedra Nicolet, Krzysztof Mrózek, Mark J. Routbort, Keyur P. Patel, Christopher J. Walker, Jill Buss, Andrew R. Stiff, Andrea Laganson, Courtney D. DiNardo, Naval G. Daver, Tapan M. Kadia, Farhad Ravandi, Andrew J. Carroll, Jonathan E. Kolitz, Bayard L. Powell, William G. Blum, Maria R. Baer, Guido Marcucci, Geoffrey L. Uy, Wendy Stock, Richard M. Stone, L. Jeffrey Medeiros, John C. Byrd, James S. Blachly, Robert L. Bowman, Jeffrey W. Tyner, Sanam Loghavi, Ann-Kathrin Eisfeld, Linde A. Miles · 2026

Read Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia by Darren Lee, Yazan Abu-Shihab, Kate Plas, Deedra Nicolet, Krzysztof Mrózek, Mark J. Routbort, Keyur P. Patel, Christopher J. Walker, Jill Buss, Andrew R. Stiff, Andrea Laganson, Courtney D. DiNardo, Naval G. Daver, Tapan M. Kadia, Farhad Ravandi, Andrew J. Carroll, Jonathan E. Kolitz, Bayard L. Powell, William G. Blum, Maria R. Baer, Guido Marcucci, Geoffrey L. Uy, Wendy Stock, Richard M. Stone, L. Jeffrey Medeiros, John C. Byrd, James S. Blachly, Robert L. Bowman, Jeffrey W. Tyner, Sanam Loghavi, Ann-Kathrin Eisfeld, Linde A. Miles (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13421326.txt.

Description

Darren Lee leads a large team reporting, in 2026, the first comprehensive account of BRAF mutations in acute myeloid leukaemia. Changes in the pathway BRAF belongs to are common in this leukaemia. They usually hit the genes NRAS and KRAS. BRAF itself is changed rarely, and it has been linked to poor outcomes.

Among 5,779 fully profiled patients at two major American cancer centres, about one percent carried BRAF mutations, mostly outside the well-known V600 hotspot and often in leukaemia arising from prior marrow disorders. Single-cell profiling showed mutation-specific patterns of partner mutations and cell identity. Survival was poor on current treatments, including venetoclax-based regimens. Drug sensitivity data, the authors argue, point toward tailored options for this small subgroup.

Catalog record

CREATORDarren Lee, Yazan Abu-Shihab, Kate Plas, Deedra Nicolet, Krzysztof Mrózek, Mark J. Routbort, Keyur P. Patel, Christopher J. Walker, Jill Buss, Andrew R. Stiff, Andrea Laganson, Courtney D. DiNardo, Naval G. Daver, Tapan M. Kadia, Farhad Ravandi, Andrew J. Carroll, Jonathan E. Kolitz, Bayard L. Powell, William G. Blum, Maria R. Baer, Guido Marcucci, Geoffrey L. Uy, Wendy Stock, Richard M. Stone, L. Jeffrey Medeiros, John C. Byrd, James S. Blachly, Robert L. Bowman, Jeffrey W. Tyner, Sanam Loghavi, Ann-Kathrin Eisfeld, Linde A. Miles
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE29926
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13421326

Browse the full library · About the Tower of Babel